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to vary by the academic centre appraising the submission, reflecting the 
inherent objectivity and uniform implementation of NICE methodology.  
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CAN INDIVIDUAL HEALTH TECHNOLOGIES IMPROVE OVERALL CHRONIC 
DISEASE MANAGEMENT?  
Brener SS1, Nikitovic M1, Krahn MD2, Goeree R3, Levin L1 
1Health Quality Ontario, Toronto, ON, Canada, 2Toronto Health Economics and Technology 
Assessment (THETA) Collaborative, Toronto, ON, Canada, 3PATH Research Institute, McMaster 
University, Hamilton, ON, Canada  
OBJECTIVES: Chronic disease is resource intensive for health care systems. 
Considerable efforts have focused on the management of chronic disease in the 
community setting however the role of individual health technologies is often 
overlooked. The purpose of this analysis was to identify examples of individual 
health technologies that contribute to overall chronic disease management. 
METHODS: The Medical Advisory Secretariat (MAS) in Ontario has published a 
substantive body of evidence-based analyses on health technologies. The MAS 
Ontario Health Technology Assessment Series was searched for reports 
published between 2006 and 2011. Findings were limited to analyses that 
reported on health technologies with moderate to high quality evidence of 
effectiveness for chronic disease management. Outcomes of interest included 
health resource utilization, patient and clinical outcomes, and economic 
analyses measures. RESULTS: Two technologies had direct evidence of the cure 
of chronic disease. Bariatric surgery was effective in the resolution of diabetes 
among morbidly obese adults (77% resolution; 95% CI 71%-83%), with a cost of 
$15,697 Canadian dollars (CAD) per quality-adjusted life year (QALY) relative to 
usual care. Ablation for atrial fibrillation resulted in greater freedom from 
arrhythmia than medical treatment alone (RR 0.30; 95% CI 0.11-0.79), and 
downstream cost savings. Two technologies were effective in the prevention of 
chronic wounds and 8 technologies were effective in the management of chronic 
obstructive pulmonary disease, stroke, coronary artery disease, congestive heart 
failure or benign prostatic hyperplasia. Among these 10 technologies, all 5 
analyses that reported incremental cost-effectiveness ratios were cost-effective 
based on a $50,000 (CAD) per QALY threshold. CONCLUSIONS: This review 
demonstrates that individual health technologies can be both effective and  
cost-effective in the overall management of chronic disease. Therefore  
health technologies can be a viable contributing factor to chronic disease 
management and should be considered as an integral component of community 
health care.  
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SCORING INNOVATION AND CLINICAL BENEFIT FOR THE ALLOCATION OF 
FUNDS – A COMPARISON OF THE GERMAN AND FRENCH PRICING SYSTEMS  
Purchase JL1, Moïse P2 
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OBJECTIVES: To compare the German (AMNOG) and French (ASMR) category 
scoring pricing systems; and to evaluate whether the two agencies have a similar 
interpretation of innovation and clinical benefit of the same drugs. Our results 
then allow us to theorize the future of European scoring systems. METHODS: A 
search of the G-BA website was conducted to identify all drug-related Health 
Technology Assessments (HTA) published between January 2011 and December 
2012. Once a list of assessments was compiled, we searched the HAS website to 
identify the same drug HTAs published within the same time period. Then, for 
both agencies we identified and compared the methods in which they scored 
both innovation and clinical benefits of these drugs. To note: Germany (G-BA) 
provide AMNOG scorings from 1 (substantial benefit) to 6 (negative additional 
benefit), whilst France (HAS) provide ASMR scorings from I (major improvement) 
to V (no improvement). RESULTS: In this time period, sixteen HTAs were 
published by the G-BA, corresponding to 12 HTAs published by HAS. Upon 
observation of the scoring comparisons, only 3 of the 12 drugs were given the 
same scores by both agencies: Fampridine (AMNOG 5; ASMR V); Cabazitaxel 
(AMNOG 3; ASMR III); Linagliptin (AMNOG 5; ASMR V). For the remaining 12 
drugs, there appeared to be little alignment in the scorings of innovation and 
clinical benefits: Vemurafenib (AMNOG 2; ASMR III), Vandetanib (5; IV), 
Belatacept (3; V), Apixaban (3; IV), Eribulin (6; IV), Collagenase clostridium 
histolyticum (5; no score), Abiraterone acetate (5; III), Fingolimod (3; IV) and 
Ticagrelor (2 and 5; IV). CONCLUSIONS: There does not seem to be a strong 
relationship between the criteria scoring of AMNOG and ASMR, demonstrating 
the heterogeneity of the European market. Whether increased HTA co-operation 
will align scoring more closely, or increased Value Based Pricing structures will 
drive divergence, is yet to be seen.  
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AN INVESTIGATION INTO THE KEY DRIVERS INFLUENCING THE DECISION 
MAKING OF THE SCOTTISH MEDICINES CONSORTIUM  
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OBJECTIVES: The main aim of this study was to identify significant implicit and 
explicit factors which play a role in decision making of the Scottish Medicines 
Consortium (SMC). Once these factors have been identified, the degree to which 
they influence the final decision will be ascertained. METHODS: A retrospective 
sample of submissions was taken from the SMC website. A bivariate statistical 
analysis was performed on the data extracted, allowing identification of the 
most fundamental drivers of an SMC decision. RESULTS: Between January 2006 
and September 2011, 577 appraisals were made by the SMC. Of these appraisals, 
27% accepted for full use, 30% were accepted for restricted use, whilst 43% of 
submissions were not recommended for use in Scotland. During this time period, 
the mean ICER for drugs accepted for use is £30,013 and for those that were not 
recommended for use the value was £38,132. Analysis of over 500 submissions to 
the SMC showed that a number of explicit, key drivers in line with SMC criteria 
were significant, including; the unofficial £30,000 ICER limit, the use of 
appropriate economic and clinical comparators, as well as robust demonstration 
of the economic case. Other key drivers which are more implicit, yet critical to 
decision making, were also shown to be significant. These included; the orphan 
status, submissions targeting paediatric populations and restrictions on the 
therapeutic scope of submissions placed by manufacturers. CONCLUSIONS: 
From a manufacturer point of view understanding the tendencies of the SMC is 
critical, as a firmer understanding of the key determinants of the SMC decision 
may lead to improved quality and robustness of future submissions. From the 
perspective of the SMC and the wider society, these insights will allow the public 
and the SMC to review the drivers of the decisions to establish whether they are 
in line with official criteria.  
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OBJECTIVES: Many non-drug technologies with regulatory approval fail to be 
recommended for reimbursement. Reasons include low quality evidence or lack 
of relevance Excellence in Clinical Innovation and Technology Evaluation 
(EXCITE) is a collaboration between industry, government and academia to 
develop a harmonized pre-market evaluation that mitigates risk, improves 
adoption, and responds to system needs METHODS: EXCITE works with industry 
to evaluate evidence of efficacy and safety, cost effectiveness and adoption 
realities. It builds on Ontario’s field evaluation experience. Structure: 1) 
Management board representing industry, government, academia and the 
Ontario Health Technology Advisory Committee (OHTAC); 2) Scientific 
collaboration of 7 Methodological Centres (MC) and 24 Academic Health Science 
Centres and a Quality Assurance Committee; and 3) Chief Scientific Officer and 
secretariat. Process: The management board prioritizes applications based on 
innovation, relevance, and commercialization. MCs develop a protocol and 
budget for clinical evaluation, systematic review, and an economic analysis. 
Human factors and usability analysis, and preference studies are offered. 
Consideration is underway for conditions of early adoption. Studies are funded 
by industry through MaRS, which fosters and commercializes innovation. 
RESULTS: Of 17 applications (year 1), 3 have commenced evaluation, 3 are in 
protocol development, discussions ongoing in 3 and one declined. Studies are 
designed to satisfy regulatory and reimbursement requirements and reflect 
complexities of adoption while maintaining high academic standards. Lessons 
learnt include a better understanding of the complexities of adoption and the 
benefit of endorsement in mitigating risk; limited funding for evaluations; 
tension between needs of industry and independence and objectivity of MCs; 
and intricacies of contract structures. CONCLUSIONS: EXCITE is a potential 
alternative to post-market HTA in Ontario, and may improve adoption in other 
jurisdictions. Expansion to a national and international scale will provide global 
reach for evaluated technologies. This is a potentially innovative and powerful 
model of early HTA.  
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ROLE OF SUBGROUP ANALYSES FOR HEALTH TECHNOLOGY  
ASSESSMENTS  
Aggarwal S, Topaloglu H 
Novel Health Strategies, Bethesda, MD, USA  
OBJECTIVES: Cost effectiveness analyses play a critical role in determining 
coverage of novel drugs and devices. Increasingly, payers are demanding 
subgroup analyses to determine indications which would be covered by  
the national health system or insurance agency. METHODS: To understand  
and review trends in the use of subgroup cost effectiveness analysis, we 
analyzed NICE HTAs for products approved between 2011-2012. Manufacturer 
submissions for CEA were compared to final review and decision by HTA agency. 
Analogs were identified and case studies were developed to further understand 
the use of subgroup analyses and cost effectiveness models. RESULTS: Decisions 
made by NICE in 2011-2012 show increasing trends towards the use of subgroup 
analysis for determining indications for coverage by national payer bodies. 
Between 2011-2012, 80% of the assessments included subgroup analyses. 
Approximately half of them included cost effectiveness analyses for various 
subgroups. Interestingly, the ICER values estimated by NICE for the same 
subgroups showed a large variation (1X-3X fold difference) compared to ICER 
values estimated by manufacturers. Selected case studies highlighted that for 
several products, NICE is recommending treatments only for subgroups whose 
ICER values are within the cost effectiveness threshold. CONCLUSIONS: New 
products need robust broader population and subgroup analyses for insurance 
coverage.  
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HEALTH CARE USE & POLICY STUDIES – Patient Registries & Post-Marketing 
Studies 
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REGISTRY OF PATIENT REGISTRIES (ROPR): PURPOSE, DESIGN AND EARLY 
EXPERIENCE  
Gliklich RE1, Levy D1, Campion DM1, Leavy MB1, Karl J1, Berliner E2, Taylor T1, Hossfeld 
W1, Khurana LL1, Thompson D3 
1Quintiles Outcome, Cambridge, MA, USA, 2Agency for Healthcare Research and Quality (AHRQ), 
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OBJECTIVES: Patient registries are important tools for health care research. The 
goal of this project, sponsored by the Agency for Healthcare Research and 
Quality (AHRQ), is to design and implement the Registry of Patient Registries 
(RoPR), the first searchable, public database designed specifically to provide 
information about registries. The RoPR is integrated with ClinicalTrials.gov, 
supports research collaboration, reduces redundancy, and improves 
transparency in observational clinical research. METHODS: The RoPR consists of 
a registration system and a public search Web site. The registration system 
collects over forty data elements which define a registry profile. The search site 
serves as a central listing of registries and includes options to filter for relevant 
profiles. RoPR registration is integrated with ClinicalTrials.gov: users registering 
a study on ClinicalTrials.gov who designate it as a patient registry are presented 
with a pop-up window displaying the RoPR registration system. Users complete 
and submit the requested data elements, creating a registry profile in the RoPR 
that is linked to the ClinicalTrials.gov listing through a unique identifier, the NCT 
ID. RESULTS: The RoPR was launched on December 1, 2012. As of January 11, 
2013, 54 new patient registries are registered on ClinicalTrials.gov. Twelve of 
these have been fully published in the RoPR, representing 21 different condition 
areas. Most are classified as disease/disorder/condition (67%), drug (33%), and/or 
procedure (33%) registries. Reported registry purposes include effectiveness 
(50%), safety or harm (42%), natural history of disease (42%) and clinical practice 
assessment (33%). A total of 67% of registry sponsors are open to being contacted 
for collaboration, data access, investigator or patient participation, or for 
information requests. CONCLUSIONS: The RoPR is a searchable Web site used by 
registry sponsors to publish information about registries and by members of  
the public to search for information about existing registries. Integration  
with ClinicialTrials.gov presents a user-friendly interface to encourage 
registration.  
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POST-MARKETING REQUIREMENTS: AN OVERVIEW OF THE THERAPEUTIC 
AREAS TARGETED BY THE EMA AND THE FDA  
Caron M1, Emery MP1, Maier W2, Escanez-Virieux MP1 
1MAPI Research Trust, Lyon, France, 2Registrat-Mapi, London, UK  
OBJECTIVES: Post-marketing requirements (PMRs) include studies and clinical 
trials that sponsors are requiredto conduct under one or more statutes or 
regulations. The objective of this research is to identify which therapeutic areas, 
and within these areas, which therapeutic indications have been subjected to the 
highest number of PMRs from the Food and Drug Administration (FDA, USA) and 
the European Medicines Agency (EMA, EU). METHODS: The Post-Marketing 
Requirements Database was used to explore requirements for post-approval 
studies published on the websites of the FDA and the EMA since 2005. The 
search was performed on January 2, 2013. RESULTS: The therapeutic area for 
which the EMA required the highest number of studies was “factors influencing 
health status and contact with health services” (n=36) for the indication 
“prophylaxis of influenza in a pandemic situation” (n=36). Within this indication, 
ten different products were concerned with Pandemrix and Cepalvan being the 
products with the highest number of studies requested (n=6 for each product). In 
comparison, the FDA had requested only 27 studies for the same therapeutic 
area, and neither Pandemrix nor Cepalvan were approved in the USA. The area 
for which the FDA requested the highest number of studies was “endocrine, 
nutritional and metabolic diseases” (n=80), and within this area, the more 
populated indication was “diabetes mellitus”(n=41). Within this indication, 
Onglyza, Byetta and Victoza were the products with the highest number of 
studies requested (n=4, 5, and 6 respectively). In comparison, the EMA had 
requested only 14 studies for the same area. Onglyza, Byetta and Victoza were 
approved in Europe but not subjected to PMRs. CONCLUSIONS: This brief review 
showed discrepancies in PMRs between the FDA and the EMA. More research is 
needed to explain these differences.  
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PATIENT REGISTRIES  
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Taylor T1, Hossfeld W1, Thompson D 
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OBJECTIVES: Patient registries are important tools for health care research, but 
variations in definitions of outcome measures and their data elements make it 
difficult to compare or link data from different registries. Standardizing outcome 
measures would help identify registries capturing similar information and 
promote collaboration, reduce redundancy, and improve efficiencies of new 
registries using standardized data elements. The goal of this project, sponsored 
by the Agency for Healthcare Research and Quality (AHRQ), is to develop a 
prototype of an Outcome Measures Framework (OMF) for use within the Registry 
of Patient Registries (RoPR) to collate and characterize the outcome measures 
currently used in patient registries. The long-term objective of the OMF is to 
support efforts to standardize outcome measures. METHODS: Stakeholders from 
a broad range of organizations (e.g., clinicians, registry sponsors, researchers, 
government agencies) were identified and invited to participate in a series of 
meetings to gather and refine the design requirements for the OMF. 
Requirements were also refined through user acceptance testing. Over 110 
individuals participated in OMF design activities. RESULTS: Stakeholders 
identified several challenges necessary to address in designing the OMF. They 
want a framework that 1) distinguishes between outcome measures collected on 
a patient level and those collected or calculated on a population level; 2) 
describes the frequency or timeframe in which a particular outcome measure is 
collected; 3) identifies outcome measures that are clinically equivalent to each 
other and clearly displays this information; and 4) minimizes user burden, since 
participation in the RoPR is currently voluntary. CONCLUSIONS: By using a 
design process that solicited the opinions of a wide variety of stakeholders, 
several challenges were identified. These challenges were addressed in the 
design of the OMF prototype, and will require further clarification if the OMF is 
developed and implemented into a system such as the RoPR.  
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OBJECTIVES: Multimorbidity has a negative impact on health-related quality of 
life (HRQL). Previous studies included only a limited number of frequent 
conditions and their combinations. The aim of this study was to analyse the 
relative impact of a large number of chronic conditions on overall HRQL in 
multimorbid patients. METHODS: This analysis is based on the MultiCare Cohort 
study, a multicenter, prospective cohort study of 3189 multimorbid primary care 
patients aged 65 to 85. The impact of 45 conditions on HRQL was analysed. The 
severity of the conditions was rated between 0 (insignificant) and 4 (very severe). 
The EQ-5D, a questionnaire consisting of 5 items (dimensions) and a visual-
analogue-scale (EQ VAS) was employed to measure HRQL. Data were analyzed 
using multiple ordinary least squares regression and multiple logistic regression. 
RESULTS: Multimorbidity measured by a weighted count score was significantly 
associated with lower overall HRQL (EQ VAS). Parkinson´s disease had the most 
pronounced negative effect on overall HRQL (EQ VAS), followed by rheuma, 
depression, obesity and cardiac insufficiency. With regard to the individual EQ-
5D dimensions, depression and obesity affected all five dimensions of the EQ-5D 
negatively except for the dimension anxiety/depression. Obesity had a positive 
effect on this dimension. Cardiac insufficiency was associated with three 
dimensions. The dimensions `self-care´ and `usual activities´ were most strongly 
affected by Parkinson´s disease. CONCLUSIONS: The overall HRQL of 
multimorbid patients decreases with an increasing count and severity of 
conditions. Parkinson´s disease, depression and obesity have the strongest 
impact on health-related quality of life.  
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SELF-RATED HEALTH MEASURES WITH DIFFERENT REFERENCE POINTS AND 
MORTALITY  
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OBJECTIVES: Self-rated health (SRH) has been shown to be a good predictor of 
mortality. However, there are mixed findings of the association between 
mortality and SRH measures with different reference points (i.e., with respect to 
either global or peer age group). This study assessed whether SRH measures with 
different reference frames influence the association of the SRH and mortality in 
old population. METHODS: We analyzed data from 2000-2005 Medical 
Expenditure Panel Survey (MEPS) respondents in Panel 5-7, aged 60 or over, 
linked to the National Death Index (NDI) through 2006. To test whether the SRH 
measures with different reference points were comparable measures to predict 
mortality, two SRH measures (global and age-comparative SRHs) were applied 
separately and concurrently. Cox proportional hazards model was conducted, 
adjusted for demographic and social characteristics. RESULTS: A total of 4787 
respondents were included in the analysis. More respondents were likely to 
assess their health as excellent or very good on the age-comparative SRH 
measure than on the global SRH measure (excellent, 14.7% vs. 7.6%; very good, 
28.6% vs. 25.8%, respectively). In the independent models, ‘poor’ SRH ratings 
were the strongest predictor of mortality. Poor global SRH ratings increased 
mortality risk by 5.06 times and poor age-comparative SRH rating increased 
mortality risk by 5.02 times compared to their respective excellent ratings. When 
two measures were concurrently analyzed in the relation to mortality risk, both 
measures significantly predicted mortality and poor global SRH ratings were the 
strongest predictor of mortality (Hazard ratio = 2.75; 95% CI = [1.694, 4.469]). 
CONCLUSIONS: In this study, both global and age-comparative SRH measures 
were associated with increased risk of mortality. However, we also found that 
the global SRH measure tended to have more predictive power than the age-
comparative measure. Our findings imply that the different reference points may 
affect the association between SRH measures and mortality.  
